4.30

1.23% 0.24

Camp 4 Therapeutics Corp (CAMP)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché CAMP Giù? Forum Previsione Frazionamento azionario

Precedente Chiudi:

$4.06

Aprire:

$4.01

Volume 24 ore:

28,816

Relative Volume:

0.16

Capitalizzazione di mercato:

$218.61M

Reddito:

$3.50M

Utile/perdita netta:

$-80.40M

Rapporto P/E:

-1.6724

EPS:

-2.5711

Flusso di cassa netto:

$-29.83M

1 W Prestazione:

-1.44%

1M Prestazione:

-11.61%

6M Prestazione:

-3.29%

1 anno Prestazione:

+87.67%

Intervallo 1D:

$4.00

$4.35

Intervallo di 1 settimana:

$3.80

$4.37

Portata 52W:

$1.305

$7.75

Camp 4 Therapeutics Corp Stock (CAMP) Company Profile

Nome

Camp 4 Therapeutics Corp

Settore

Healthcare (1115)

Industria

Biotechnology (621)

Telefono

617-651-8867

Indirizzo

ONE KENDALL SQUARE, CAMBRIDGE, CA

Dipendente

Cinguettio

@calamp

Prossima data di guadagno

2026-05-12

Ultimi documenti SEC

CAMP's Discussions on Twitter

Compare CAMP vs VRTX, REGN, ARGX, ALNY, ONC

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
CAMP Camp 4 Therapeutics Corp	4.21	210.82M	3.50M	-80.40M	-29.83M	-2.5711
VRTX Vertex Pharmaceuticals Inc	426.32	108.54B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	710.25	75.59B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	781.72	50.22B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	295.00	40.45B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	315.66	32.51B	5.36B	287.73M	924.18M	2.5229

Camp 4 Therapeutics Corp Stock (CAMP) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-04-14	Iniziato	Rodman & Renshaw	Buy
2025-10-02	Iniziato	Cantor Fitzgerald	Overweight
2025-09-16	Downgrade	JP Morgan	Overweight → Neutral
2025-05-27	Iniziato	Wedbush	Outperform
2024-11-05	Iniziato	JP Morgan	Overweight
2024-11-05	Iniziato	Piper Sandler	Overweight
2024-11-05	Iniziato	William Blair	Outperform
2022-08-16	Aggiornamento	Craig Hallum	Hold → Buy
2021-12-22	Downgrade	Craig Hallum	Buy → Hold
2021-09-24	Reiterato	Craig Hallum	Buy
2021-06-25	Reiterato	Craig Hallum	Buy
2020-12-18	Downgrade	JP Morgan	Neutral → Underweight
2020-04-17	Aggiornamento	Jefferies	Hold → Buy
2020-03-05	Reiterato	Craig Hallum	Buy
2019-12-20	Reiterato	Craig Hallum	Buy
2019-12-20	Downgrade	First Analysis Sec	Outperform → Neutral
2019-06-28	Aggiornamento	Northland Capital	Market Perform → Outperform
2019-05-29	Downgrade	Goldman	Neutral → Sell
2019-05-01	Reiterato	Craig Hallum	Buy
2019-03-25	Downgrade	JP Morgan	Overweight → Neutral
2019-01-25	Aggiornamento	JP Morgan	Neutral → Overweight
2018-12-21	Aggiornamento	Craig Hallum	Hold → Buy
2018-12-14	Reiterato	B. Riley FBR	Buy
2018-12-11	Downgrade	First Analysis Sec	Strong Buy → Outperform
2018-12-11	Downgrade	Northland Capital	Outperform → Market Perform
2018-11-27	Iniziato	Goldman	Neutral
2018-10-15	Iniziato	Jefferies	Hold
2018-09-28	Reiterato	Craig Hallum	Hold
2018-04-27	Reiterato	Craig Hallum	Hold
2018-03-08	Downgrade	Craig Hallum	Buy → Hold
2018-02-16	Aggiornamento	First Analysis Sec	Equal-Weight → Overweight

Mostra tutto

Camp 4 Therapeutics Corp Borsa (CAMP) Ultime notizie

Apr 30, 2026

Camp4 Therapeutics Corp engages with SYNGAP1 families to inform regRNA therapeutic progress - Traders Union

Apr 30, 2026

Apr 28, 2026

CAMP4 Therapeutics Preprints Pioneering Study on Regulatory RNA Profiling and Gene Upregulation - The Manila Times

Apr 28, 2026

CAMP4 maps thousands of new RNAs for gene-boosting drugs - Stock Titan

Apr 28, 2026

Apr 26, 2026

Camp4 Therapeutics shares slide after $30 million equity offering priced - MSN

Apr 26, 2026

Apr 23, 2026

CAMP4 (CAMP) details director votes, auditor ratification and equity plan - Stock Titan

Apr 23, 2026

[ARS] Camp4 Therapeutics Corp SEC Filing - Stock Titan

Apr 23, 2026

Apr 18, 2026

CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sahm

Apr 18, 2026

Apr 17, 2026

CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Short Interest Down 14.2% in March - MarketBeat

Apr 17, 2026

Three new CAMP4 hires get stock options at $4.59 a share - Stock Titan

Apr 17, 2026

Apr 15, 2026

Camp4 Therapeutics Corp boosts team engagement with employee event on the slopes - Traders Union

Apr 15, 2026

CAMP4 Therapeutics (NASDAQ:CAMP) Upgraded to "Strong-Buy" at Rodman & Renshaw - MarketBeat

Apr 15, 2026

Apr 14, 2026

Rodman & Renshaw initiates CAMP4 Therapeutics stock with buy rating By Investing.com - Investing.com Australia

Apr 14, 2026

Rodman & Renshaw initiates CAMP4 Therapeutics stock with buy rating - Investing.com

Apr 14, 2026

Apr 13, 2026

CAMP4 Therapeutics Unveils Gene-Upregulation ASO Platform, Targets SYNGAP1 Clinic Entry in 2H - MarketBeat

Apr 13, 2026

Apr 09, 2026

Life sciences leaders unite at Camp4 Therapeutics Corp-backed event supporting health equity - Traders Union

Apr 09, 2026

Apr 08, 2026

CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat

Apr 08, 2026

Apr 07, 2026

CAMP Technical Analysis | Trend, Signals & Chart Patterns | CAMP4 THERAPEUTICS CORP (NASDAQ:CAMP) - ChartMill

Apr 07, 2026

Apr 06, 2026

Camp4 Therapeutics Corp advances creative strategies in complex drug discovery partnerships - Traders Union

Apr 06, 2026

Is CAMP4 (CAMP) Stock Good for Beginners | Price at $4.72, Up 5.59%Aggressive Growth Stocks - Newser

Apr 06, 2026

Apr 03, 2026

Camp4 Therapeutics (CAMP) grants 170,000 stock options to Chief Scientific Officer - Stock Titan

Apr 03, 2026

Camp4 Therapeutics (CAMP) CMO receives 215,000 stock options grant - Stock Titan

Apr 03, 2026

Camp4 Therapeutics (CAMP) CFO receives 215,000 stock options grant - Stock Titan

Apr 03, 2026